Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Canaccord Genuity hikes target price on Zegona Communications

(Sharecast News) - Analysts at Canaccord Genuity hiked their target price on Zegona Communications from 835.0p to 980.0p on Monday following the group's recent FY25 results. Canaccord Genuity noted there was no new news on Zegona's fixed network monetisation in its FY25 results, other than it was "well-advanced", making this "a good opportunity" for investors to focus on the strong execution of the company's operational turnaround.

In addition to the "impressive operational transformation", Canaccord Genuity continues to believe Zegona can extract more than €2.0bn from a combination of dividend recaps and equity stake sales from its two Netco JVs.

"This should enable it to pay a special dividend of c.£1.6/share (~20% of mkt cap), allowing the subsequent cancelation of EJLSHM's 69% stake. The reduction in share count would imply 'look-through' value of £7.5-15/share, based on peer multiples," said the Canadian bank, which reiterated its 'buy' rating on the stock.

"Our estimate upgrades flow through to a raised target price of 980p from 825p. This is based on a blend of: 1) an 80% weighting assigned to the average of different proforma post-Netco monetisation valuations (4.5x to 6.5x FY26e EV/adj. EBITDAaL); and 2) a 20% weighting of a standalone/'ex Netco monetisation' valuation based on a 5.5x CY26E EV/adj. EBITDAaL multiple."

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.